We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting share. Looking at the news around looks like they are growing at a good pace. Definitely doing a bit more research here, with the idea of buying....
Shares are incorrectly shown as sells here. Buys on other sites. Huge number of buys first thing following very strong buy recommendation in Daily Mail yesterday. It persuaded me and I bought this morning. A prime candidate to be bought out in my book. Fingers crossed
What’s occurring????
Trades showing as sells but up 40%…….anyone got any ideas?
Troajan thx
On my watch list!
https://www.thisismoney.co.uk/money/investing/article-11975873/MIDAS-SHARE-TIPS-Seeking-healthy-growth-Try-Intelligent-Ultrasound.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.195388261.87470016.1681593170-829466088.1679172563&_gl=1*zg95li*_ga*ODI5NDY2MDg4LjE2NzkxNzI1NjM.*_ga_XE0XLFFF16*MTY4MTU5MzE3MC43LjEuMTY4MTU5MzE5Mi4wLjAuMA..
Welcome to the first SonoGram of 2023!
In this edition, our customers tell us how they are utilizing our simulator products in their training programs, we bring you the latest updates on NeedleTrainer and HeartWorks 3D Echo, find out where you can meet the IU team at in-person and online events, and discover the latest industry news.
Https://www.intelligentultrasound.com/wp-content/uploads/2023/04/Sonogram-Q1-2023.html
Intelligent Ultrasound Group plc, a company that specializes in "classroom to clinic" ultrasound technology and artificial intelligence (AI) software and simulation, recently released a trading update announcing that their revenue for the year ending December 2022 is expected to increase by 33% to £10.1m (2021: £7.6m). The company's simulation revenue is expected to have grown by 28% to £9.4m (2021: £7.4m), driven by strong sales in the UK. Additionally, the company's direct to market sales in the UK and US are expected to have grown by almost 50% to £7.7m (2021: £5.2m). However, the company's reseller markets in Europe and Asia are expected to have decreased by 19% to £1.7m (2021: £2.2m), largely due to the impact of COVID-19 on the Chinese market.
The company's clinical AI related revenue is expected to have grown by over 220% to £0.7m (2021: £0.2m), exceeding market expectations and demonstrating that the company's AI-related products are beginning to gain commercial traction. The company remains confident in its "classroom to clinic" ultrasound business strategy and expects to continue to grow its simulation and AI-related revenue in 2023.
In November 2022, the company also announced that it had raised £5.2m (net: £4.8m) from shareholders via a placing, increasing their cash at bank as of December 2022 to £7.2m (December 2021: £5.0m). CEO Stuart Gall commented on the positive progress the company has made and their excitement for the long-term potential of the "classroom to clinic" business.
Positives:
1) The company has reported a 33% increase in revenue for the year ending December 2022, with simulation revenue growing by 28%.
2) Direct to market sales in the UK and US have grown by almost 50%.
3) Clinical AI related revenue has grown by over 220%, exceeding market expectations and demonstrating commercial traction for the company's AI-related products.
4) The company raised £5.2m from shareholders in November 2022, increasing their cash at bank to £7.2m.
5) CEO Stuart Gall is confident in the long-term potential of the company's "classroom to clinic" business strategy.
Negatives:
1) The company's reseller markets in Europe and Asia have decreased by 19%, largely due to the impact of COVID-19 on the Chinese market.
All going in right direction……encouraging
Rns trading update shows revenue growth, good cash position and signals where transformational growth will come from (AI). Happy as a medium to long term hold.
Good interview
Link curiosity 40 Fathoms on ADVFN
https://www.**********.co.uk/articles/intelligent-ultrasound-year-in-review-on-the-path-to-profitability-41485fe
"By classifying ScanNav Anatomy Peripheral Nerve Block (PNB) under its de novo programme, the FDA has concluded that there are no devices already on the market which meet the same clinical need. It has therefore created the new generic type of device classification of real-time anatomy visualization and labelling device for ultrasound guided regional anaesthesia."
£10m expected revenue this year, targeted £25m for 2025, cash in bank, potential new products to market place. £24m Mcap. A buy IMHO.
Interested to see what they are looking to research with it. Will definitely be one to watch though
so, there it is. Placing was obviously coming, at least the price isn't too bad compared to current sp. 30% discount to the sp when the insiders started selling though.
too many sells, another 100k sell gone through. Not saying there is something up, just makes me too nervous to buy what looks like a gift.
Shares here are to scarce. Look one small trade at 9.88 moves the ask up again. I seem to be only one shouting but soon enough it will blow
SP at year low yet look
Financial highlights
· Growth in revenue of 62% to £5.9m (H1 2021: £3.6m)
o Simulation revenue increased by 56% to £5.6m (H1 2021: £3.6m)
o Clinical AI revenue, which is in the early stage of commercialisation, increased by 486% to £0.3m (H1 2021: £0.1m)
· Operating loss for the period narrowed to £1.3m (H1 2021: loss of £2.3m)
· Cash and cash equivalents at 30 June 2022 of £3.5m (31 December 2021: £5.0m)
This will boom soon once some volume takes notice. If end of year results are as good then this company ifs definitely a multibagger in the making
Don’t know why on earth this has dropped below 10p. Worldwide AI medical simulator sales, lots of cash and massive potential. However have seen a few trades going in below 10p so hopefully it will recover back towards 15p soon enough
Nice buy to set us off. One more like that and it should start a momentum run. Watch how each trade moves the SP. Shares are are extremely scarce
Movement ?????? single trades move this SP . 10.5p to buy now. Absolutely no reason why this should not be at least 20p. 2 products now selling in US with FDA approval. Unique medical AI systems linked in with GE medical. At year low of 10.5p tick tock
By classifying ScanNav Anatomy Peripheral Nerve Block (PNB) under its de novo programme, the FDA has concluded that there are no devices already on the market which meet the same clinical need. It has therefore created the new generic type of device classification of real-time anatomy visualization and labelling device for ultrasound guided regional anaesthesia.
The product is unique and is the second FDA clearance for IUG following the success of ScanNav assist which already has FDA clearance and is selling in the USA. I do not know how this company is at year low SP ... Revenue up to 5.8 million over a year. 5m in cash. Very low share issue and fantastic global AI medical training and realtime simulation products also selling around the world . MCAP is stupidly low and to me we should be closer to 50p not 10p
Think most people must of missed this RNS last week. It’s huge news to get a product through FDA clearance to sell in the states and yet the SP drops to year low ??? It will move rapidly once attention is found
Feel 2023 could be a very good year for IUG. Under the radar and severe lack of volume always causes drops here. Products are amazing and US should bring into great revenue. One to enter at low levels and await patiently for its growth
Toffee
You could be correct about a placing upcoming as Kepler yesterday released a "puff" video on them, often a good sign that a company wishes to raise its profile.
Trading update was fine a while back, approval for new product in USA today yet just more sells. Placing coming? Cant work it out, looks a stinking buy.
Not quite a jam tomorrow Rns, solid growth, increasing partner support and China constraints easing.
The race is on between R&D burn / cost of sale versus profitable revenue. Good signs, but earliest profitability likely to be late 2023 or 2024.
Imho worth the wait.
Glalth